The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Outcomes following venetoclax monotherapy in patients with R/R WM in the real-world setting
Jorge Castillo, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the findings of a study investigating venetoclax monotherapy in the real-world setting for patients with relapsed/refractory (R/R) Waldenström’s macroglobulinemia (WM). In contrast to clinical trial settings, lower doses of venetoclax are administered, and the drug is often introduced later in the disease course. Dr Castillo emphasizes the importance of early administration of venetoclax to optimize patient outcomes. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Pharmacyclics, BeiGene, Cellectar, AstraZeneca, Mustang Bio, Kite, Loxo, Abbvie
Research Funding: Pharmacyclics, BeiGene, Cellectar, AstraZeneca, Loxo, Abbvie
